DC Field | Value | Language |
dc.contributor.author | Televca, Irina | - |
dc.date.accessioned | 2020-10-01T19:18:17Z | - |
dc.date.available | 2020-10-01T19:18:17Z | - |
dc.date.issued | 2016 | - |
dc.identifier.citation | TELEVCA, Irina. The immune process in the pathogenesis of tumors. In: MedEspera: the 6th Internat. Medical Congress for Students and Young Doctors: abstract book. Chișinău: S. n., 2016, p. 292. | en_US |
dc.identifier.isbn | 978-9975-3028-3-8. | - |
dc.identifier.uri | http://repository.usmf.md/handle/20.500.12710/11878 | - |
dc.description | Department of Physiopathology, Nicolae Testemitanu State University of Medicine and Pharmacy, Chisinau, Republic of Moldova, The 6th International Medical Congress for Students and Young Doctors | en_US |
dc.description.abstract | Introduction: The immune process in the pathogenesis of the tumors represents an actual subject
for the prevention and the treatment of the cancer, which frequency is decreasing while studying the
newest theories of the etiopathology of cancer, a disease that is the common cause of death.
The objective of this study is to review the newest methods, that explain the role of the immune
processes in the pathology and the treatment of tumors.
Material and methods: Informational support for the development of this publication has served
a full amount of current national and international journals, which are concerned with tumors, found
through the „PubMed” „Google” and „CrossRefMedlineWeb of Science”. After entering the filters: the
immune process in the pathogenesis of tumors were selected 20 sources.
Results: After studying the interaction between the immune system and the tumors, different
immunotherapies were identified: the new therapeutic monoclonal antibodies, that were approved by the
Food and Drug Administration, as a standard treatment in some forms of cancer, Associated with
trastuzumab for mamar cancer and rituximab for the B cells lymphoma, and the vaccines, which are
starting to be used in clinical practice, either alone or in various combinations.
Conclusions: Much has been learned about the potential of the immune system to control cancer
and the various ways that immunotherapy can boost the potential of the immune system for the benefit
of the patient. This knowledge has stimulated the invention of many new therapeutic antibodies, cellbased
treatments, and vaccines, which are starting to be used in clinical practice, either alone or in
various combinations. These new therapies are expected to result in improved cancer treatment and,
eventually, the prevention of cancer. | en_US |
dc.language.iso | en | en_US |
dc.publisher | MedEspera | en_US |
dc.subject | The hallmarks of cancer | en_US |
dc.subject | the immunology of cancer | en_US |
dc.subject | imunogenicity | en_US |
dc.subject | immunosuppression | en_US |
dc.subject | immunotherapies | en_US |
dc.title | The immune process in the pathogenesis of tumors | en_US |
dc.type | Article | en_US |
Appears in Collections: | MedEspera 2016
|